Renal Impairment Study of PF-06700841

• Status: Recruiting
• Trial end date: 2021-12-27
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to characterize the effect of kidney impairment on the blood concentrations of PF-06700841 and its major metabolite. Findings from this study will be used to develop dosing recommendations so that the dose and/or dosing interval may be adjusted appropriately in the presence of kidney disease.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Pfizer
• Treatments: PF-06700841

Criteria

Inclusion Criteria:

• Male or female participants who are between the ages of 18 and 75 years, inclusive, at the Screening visit.

• Body mass index (BMI) of ≥17.5 to ≤40 kg/m2; and a total body weight >50 kg.

• Normal, Severe, Moderate and Mild renal function at 2 Screening visits.

• Stable drug regimen

Exclusion Criteria:

• Renal transplant recipients.

• Urinary incontinence without catheterization.

• Subjects with clinically significant infections within the past 6 months prior to first dose of study drug, evidence of active or chronic infection requiring oral treatment within 4 weeks prior to first dose

• Known history of pulmonary embolism or recurrent deep vein thrombosis

• Any condition possibly affecting drug absorption (eg, prior bariatric surgery, gastrectomy, ileal resection).